Clinical Trials | December 21, 2025
Takeda posts strong Phase 3 win for oral psoriasis drug
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The expansion includes a larger technical and service team and increased local procurement
The new facility is expected to generate 500-600 new jobs in the region
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
